John Wells PhD Math
:
I think the problem with your portfolio performance is your model for calculating fair value of the stocks. I just looked at MED and based on a dividend discount method, I calculate the fair value to be zero. They are expecting to lose money, and I don’t see any prospect for that changing, which means that it has some assets, but they’re just going to slowly burn through the cash until there’s nothing left. I think you would be better served with VTI or VOO, the Vanguard total market ETF or the Vanguard S&P 500 ETF. With either of those at least you will match the market performance, which would put you substantially ahead of where you are.
CarilonCapital
OP
John Wells PhD Math
:
My valuation of $Medifast (MED.US)$ in this and other vids were done when the company was still profitable and had high FCF. Based on recent financials it’s clear that the company’s price collapse was not justified. I released this video a year ago. Estimating fair value still requires projecting fcf and discounting.
The company's high P/S ratio is seen as unjustified due to predicted revenue drop. While the market expects continuation of current performance, upcoming revenue decline could negatively affect stock price. Investors are advised to be cautious.